Dan Grossman joined Galapagos as Chief Strategy Officer on August 4, 2025. Dan is a seasoned biopharmaceutical strategy and business development executive with over 20 years of leadership experience at the intersection of life sciences, innovation, and organizational development. Prior to joining Galapagos, Dan served as Head of Field Building at the Psychedelic Science Funders Collaborative, where he authored a landmark investment roadmap and forged cross-sector partnerships to accelerate progress in mental health innovation. Before that, he spent two decades at Boston Consulting Group, most recently serving as Managing Director and Senior Partner in the Global Health Care Practice Area, where he led development of high-impact growth strategies, portfolio optimization, capability building and a wide range of strategic transactions for biopharmaceutical companies. His work has shaped the direction of leading therapeutics in immunology, neuroscience, and oncology, and helped build agile organizations capable of delivering long-term value. He currently chairs the Board of Directors of Lykos Therapeutics and is a Venture Partner at SeedFund Capital, supporting mission-driven ventures at the frontier of science and well-being. Dan holds a PhD in mathematics from Princeton and a BA from Harvard University, and continues to contribute to civic and cultural institutions in Chicago.
